Regencell Bioscience (NASDAQ:RGC) Trading 7.1% Higher – Should You Buy?

Shares of Regencell Bioscience Holdings Limited (NASDAQ:RGC) were up 7.1% during trading on Tuesday . The stock traded as high as $12.00 and last traded at $11.2530. 156,350 shares traded hands during mid-day trading, a decline of 44% from the average daily volume of 280,112 shares. The stock had previously closed at $10.51.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Friday, March 27th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

Regencell Bioscience Stock Down 22.7%

The business’s 50 day moving average is $24.06 and its 200 day moving average is $25.74.

Regencell Bioscience (NASDAQ:RGC) last announced its earnings results on Friday, May 8th. The company reported ($0.00) EPS for the quarter.

Institutional Investors Weigh In On Regencell Bioscience

A number of large investors have recently bought and sold shares of the company. Squarepoint Ops LLC acquired a new stake in Regencell Bioscience during the second quarter worth about $1,701,000. BNP Paribas Financial Markets purchased a new position in Regencell Bioscience during the second quarter valued at approximately $768,000. XTX Topco Ltd acquired a new position in Regencell Bioscience in the third quarter valued at approximately $598,000. Vident Advisory LLC lifted its holdings in Regencell Bioscience by 65.7% in the fourth quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock valued at $629,000 after acquiring an additional 11,866 shares during the period. Finally, Bank of America Corp DE boosted its position in Regencell Bioscience by 59,113.8% in the 1st quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock worth $437,000 after purchasing an additional 17,143 shares in the last quarter. Hedge funds and other institutional investors own 0.13% of the company’s stock.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.